Neurocrine Biosciences, Inc.
NBIX
$155.80
$5.213.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 28.76% | -26.63% | 94.88% | 1,260.76% | -92.34% |
| Total Depreciation and Amortization | -2.67% | -2.60% | 5.48% | -3.95% | 7.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -152.22% | -44.76% | 643.35% | -63.97% | 92.11% |
| Change in Net Operating Assets | -102.52% | 164.36% | -373.66% | -64.98% | -125.13% |
| Cash from Operations | -62.46% | 70.73% | 123.04% | 57.41% | -73.28% |
| Capital Expenditure | -479.17% | 118.18% | -5.60% | -16.82% | -46.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -913.20% | 69.86% | -1,012.12% | -166.27% | 140.82% |
| Cash from Investing | -856.90% | 73.11% | -578.28% | -304.23% | 120.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -36.73% | -18.20% | 216.67% | -55.14% | 221.00% |
| Repurchase of Common Stock | -- | -- | 100.00% | 88.20% | 50.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -330.83% | -18.20% | 1,481.82% | 97.20% | 59.34% |
| Foreign Exchange rate Adjustments | -- | -- | -200.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -219.77% | 389.24% | 9.01% | 279.69% | 66.49% |